Zacks: Analysts Expect Supernus Pharmaceuticals Inc (SUPN) to Post $0.30 EPS

Share on StockTwits

Wall Street analysts expect Supernus Pharmaceuticals Inc (NASDAQ:SUPN) to post earnings per share (EPS) of $0.30 for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Supernus Pharmaceuticals’ earnings. The lowest EPS estimate is $0.21 and the highest is $0.44. Supernus Pharmaceuticals reported earnings of $0.44 per share in the same quarter last year, which would indicate a negative year over year growth rate of 31.8%. The firm is expected to report its next earnings report on Tuesday, February 26th.

On average, analysts expect that Supernus Pharmaceuticals will report full-year earnings of $1.87 per share for the current year, with EPS estimates ranging from $1.78 to $2.02. For the next financial year, analysts anticipate that the business will report earnings of $2.35 per share, with EPS estimates ranging from $2.10 to $2.55. Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.43 by $0.09. The company had revenue of $102.99 million for the quarter, compared to analysts’ expectations of $100.75 million. Supernus Pharmaceuticals had a net margin of 25.89% and a return on equity of 30.30%. The firm’s revenue was up 28.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.29 earnings per share.

SUPN has been the topic of a number of analyst reports. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $44.00 price objective on shares of Supernus Pharmaceuticals in a report on Thursday, August 9th. Cantor Fitzgerald set a $57.00 price objective on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, November 7th. Mizuho initiated coverage on shares of Supernus Pharmaceuticals in a report on Monday, September 17th. They issued a “buy” rating and a $61.00 price objective on the stock. ValuEngine cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday. Finally, B. Riley dropped their price objective on shares of Supernus Pharmaceuticals from $68.00 to $65.00 and set a “buy” rating on the stock in a report on Monday, November 12th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $56.89.

Shares of SUPN stock traded down $5.47 during trading hours on Thursday, reaching $40.54. The stock had a trading volume of 2,278,263 shares, compared to its average volume of 706,231. The company has a quick ratio of 2.65, a current ratio of 2.82 and a debt-to-equity ratio of 0.77. Supernus Pharmaceuticals has a twelve month low of $34.90 and a twelve month high of $61.25. The stock has a market cap of $2.40 billion, a PE ratio of 32.17, a price-to-earnings-growth ratio of 1.45 and a beta of 0.93.

Hedge funds have recently added to or reduced their stakes in the stock. Glenmede Trust Co. NA increased its holdings in shares of Supernus Pharmaceuticals by 3.2% in the 2nd quarter. Glenmede Trust Co. NA now owns 652,806 shares of the specialty pharmaceutical company’s stock worth $39,070,000 after acquiring an additional 20,012 shares during the period. Janney Montgomery Scott LLC grew its position in Supernus Pharmaceuticals by 28.1% in the 3rd quarter. Janney Montgomery Scott LLC now owns 13,860 shares of the specialty pharmaceutical company’s stock valued at $698,000 after buying an additional 3,039 shares in the last quarter. Icon Advisers Inc. Co. bought a new position in Supernus Pharmaceuticals in the 3rd quarter valued at about $3,877,000. Oppenheimer Asset Management Inc. grew its position in Supernus Pharmaceuticals by 9.2% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 14,813 shares of the specialty pharmaceutical company’s stock valued at $746,000 after buying an additional 1,251 shares in the last quarter. Finally, Cynosure Advisors LLC grew its position in Supernus Pharmaceuticals by 55.0% in the 2nd quarter. Cynosure Advisors LLC now owns 8,260 shares of the specialty pharmaceutical company’s stock valued at $494,000 after buying an additional 2,930 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Read More: Dividend Aristocrat Index

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply